Podcasts about Combination

Join Jim and Greg for the Wednesday 3 Martini Lunch as they dig into the Democrats' hilariously bad messaging on the government shutdown, China's chilling fusion of AI and genetic engineering, and Jon Stewart's absurd comparison of Zohran Mamdani to Jackie Robinson.First, they marvel at how Democrats proudly admit to causing real pain for Americans in an attempt to gain political leverage in the shutdown fight. It's a cold, heartless message but Democrats are more than welcome to keep using it.Next, Jim shares insights from Bill Drexel of the Hudson Institute, who joined Jim on the recent trip to India. Drexel reports that China is combining artificial intelligence with genetic engineering in pursuit of future generations with no flaws and who will be superior soldiers. Jim also explains how the ethical nightmare surrounding this plan won't even matter to Xi Xinping and the Chinese Communist Party.Finally, they roll their eyes as Jon Stewart of The Daily Show fawns over Democrat New York City mayoral nominee Zohran Mamdani and compares him to legendary baseball player Jackie Robinson. Jim and Greg document how the Democrats have shifted from running away from Mamdani to a full embrace once they sensed he could win.Please visit our great sponsors:Cancel unwanted subscriptions and reach your financial goals faster with Rocket Money at https://RocketMoney.com/MARTINI Build your fall sanctuary of comfort with Boll and Branch. Save 20% plus free shipping on your first set of sheets at https://BollAndBranch.com/THREEMARTINI —offer ends soon, exclusions apply.

Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Thomas Seager, PhD is CEO of Morozko Forge ice bath company. He is also Associate Professor in the School of Sustainable Engineering & the Built Environment at Arizona State University. He's authored two books - "Uncommon Cold: The Science & Experience of Cold Plunge Therapy" & "Uncommon Testosterone: Cold Plunge Therapy for Optimizing Sexual Health." SPONSORS https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off EPISODE LINKS https://www.morozkoforge.com Uncommon Testosterone Book: https://a.co/d/6eUuE9j Uncommon Cold Book: https://bit.ly/3L7O4MU https://www.instagram.com/seagertp https://x.com/seagertp FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00 - Pre-cooling vs. post-cooling with ice baths 15:11 - Ice baths are replacing TRT 25:24 - Best length of a cold plunge 30:10 - When ice baths went mainstream 40:04 - Mitochondrial health, brown fat & cold exposure 46:04 - How the mitochondria emit visible light 55:59 - UVA vs. UVB light 01:02:32 - How often you should cold plunge 01:08:57 - Combination of sauna & cold plunge 01:17:44 - How the body survives a fast 01:25:21 - Best cure for headaches & migraines 01:37:30 - Seed oils, food dyes & sugar 01:50:27 - Why RFK is perfect for HHS 01:57:52 - How to fix nutrition in poor populations 02:05:29 - What REALLY causes autism in kids 02:14:28 - Insurance incentives for hospitals 02:22:13 - New pharmaceutical ad requirements 02:32:01 - Hot tubs make you sick Learn more about your ad choices. Visit podcastchoices.com/adchoices

Nancy Harhut, Founder of HBT Marketing, joins AMA's CEO and podcast host, Bennie F. Johnson, for a conversation about the misconceptions of B2B marketing, what happens when you employ behavioral science in marketing campaigns, and why it's always necessary to employ the brain.

The FiltrateJoel Topf @kidneyboy.bsky.social‬Swapnil Hiremath @hswapnil.medsky.socialNayan Arora captainchloride.bsky.socialSopia Ambruso @sophia-kidney.bsky.socialSpecial Guests Brendon Neuen @brendonneuen.bsky.social Associate Professor and Program Lead, Renal and Metabolic at The George Institute for Global Health. Nephrologist and Director of Kidney Trials at Royal North Shore Hospital.Neuen has had three prior appearances on Freely Filtered: EMPA Kidney, DUPLEX and Sparsentan in FSGS, FLOW and SemaglutideMuthiah Vaduganathan @mvaduganathan on X. Cardiologist at Brigham and Women's Hospital and Harvard Medical School. Assistant Professor of Medicine.Editing byJoel TopfThe Kidney Connection written and performed by Tim YauShow NotesDONATE to NephJC! Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes NEJM | NephJC SummaryFIDELIO Bakris et al, NEJM 2020 | NephJC Summary; subgroup throws doubt on efficacy of finerenone in patients on flozinsFIGARO Pitt et al, NEJM 2021; subgroups clearly shows finerenone works, flozins or notNEJM editorial (wrongly) saying do not use Flozins unless on RASi Don't use dual RAS blockade ONTARGET Yusuf et al, NEJM 2008; VA NEPHRON-D Fried et al NEJM 2013Why we cannot study finerenone in HFrEF (RALES Pitt et al NEJM 1999) Muthu is jealous of GFR slope and albuminuria surrogate endpoints and wants to borrow them for HFpEF (Inker et al EHJ 2025)Combination therapy and CV outcomes in hypertension (Wang et al JAMA Card 2024 on low dose combinations and BP; Egan et al Blood Pressure 2022 review of topic) CONFIRMATION HF trial registry entry (Finerenone and Empagliflozin in hospitalized patients with HF)23:20: Nayan and Swap miss a chance to say ‘de-flozination' to discuss stopping a flozin which would allow a patient to be included in the trial Finerenone is a CYP3A4 substrate (Heinig et al Clin Pharmacokinetics 2023); Useful list of CYP3A4 inducers and inhibitors Everyone should get an ABPM (Bugeja et al CMAJ 2022)EASiKIDNEY study design Albuminuria mediates CKD benefits with Finerenone (Agarwal et al Ann Intern Med 2023)GFR slope and Albuminuria and the FDA (Taylor et al eClin Med 2025) Dapagliflozin and Eplerenone combination crossover trial (Provenzano et al JASN 2022)Joel gets promoted! (PBFluids reflection) Bluesky NephJC Chat discussion on ‘renal remission' Withdrawal of Finerenone and worse outcomes from FINEARTS (Vaduganathan et al JACC 2025)Combination therapies Analysis from Brendan and Muthu (Neuen et al Circulation 2024)Do not use KFRE when GFR > 60 (KDIGO Practice Point 2.2.4: Note that risk prediction equations developed for use in people with CKD G3–G5, may not be valid for use in those with CKD G1–G2) Finerenone vs Spironolactone trial in Primary Aldosteronism (Hu et al Circulation 2025)FIND CKD trial design (Heerspink et al NDT 2025) FINE-ONE trial design (Heerspink et al Diab Res Practice 2023) Tubular SecretionsNayan keeping his chin up as Yankees lose and Mariners follow (MLB Playoffs)Sophia's adventures with Beekeeping (Royal Jelly?) Brendon loves listening to ‘Susan' by Raye Muthu is back into Taekwondo Swap is still reading Martha Wells (Witch King on GoodReads)Joel will be hiking the Laugavegur trail in Iceland

Featuring an interview with Dr Aaron Lisberg, including the following topics: Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) for Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): A Pooled Analysis of the TROPION-Lung01 and TROPION-Lung05 Trials (0:00) Ahn M-J et al. Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05. ESMO Asia 2024;Abstract LBA7 Ahn M-J et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol 2025;[Online ahead of print]. Abstract Sacituzumab Tirumotecan for Previously Treated Advanced EGFR-Mutated NSCLC: Results from the Randomized OptiTROP-Lung03 Study (7:08) Fang W et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: Multicentre, open label, randomised controlled trial. BMJ 2025;389:e085680. Abstract Zhang L et al. Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study. ASCO 2025;Abstract 8507. Combination of Dato-DXd and Immunotherapy as First-Line Therapy for Patients with Advanced NSCLC (13:12) Cuppens K et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4). ESMO Targeted Anticancer Therapies Congress 2025;Abstract 8O. Okamoto I et al. TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol 2024;20(37):2927-36. Abstract Levy BP et al. TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol 2023;19(21):1461-72. Abstract Aggarwal C et al. AVANZAR: Phase III study of datopotamab deruxtecan (Dato-DXd) + durvalumab + carboplatin as 1L treatment of advanced/mNSCLC. World Conference on Lung Cancer (WCLC) 2023;Abstract P2.04-02. TROP2-Targeting Antibody-Drug Conjugates as Neoadjuvant and/or Adjuvant Therapy for Patients with Resectable NSCLC (19:08) A phase III, randomised, open-label, global study of adjuvant datopotamab deruxtecan (Dato-DXd) in combination with rilvegostomig or rilvegostomig monotherapy versus standard of care, following complete tumour resection, in participants with Stage I adenocarcinoma non-small cell lung cancer who are ctDNA-positive or have high-risk pathological features (TROPION-Lung12). NCT06564844 Cascone T et al. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: The platform phase 2 NeoCOAST-2 trial. Nat Med 2025;31(8):2788-96. Abstract CME information and select publications

Keep your focus on God and pray with faith, knowing He will answer your petitions.

Keep your focus on God and pray with faith, knowing He will answer your petitions.See omnystudio.com/listener for privacy information.

Keep your focus on God and pray with faith, knowing He will answer your petitions.See omnystudio.com/listener for privacy information.

Keep your focus on God and pray with faith, knowing He will answer your petitions.

Keep your focus on God and pray with faith, knowing He will answer your petitions.

Keep your focus on God and pray with faith, knowing He will answer your petitions.See omnystudio.com/listener for privacy information.

Write down your prayer requests to better focus your mind and pray in detail.

Write down your prayer requests to better focus your mind and pray in detail.See omnystudio.com/listener for privacy information.

Write down your prayer requests to better focus your mind and pray in detail.See omnystudio.com/listener for privacy information.

Write down your prayer requests to better focus your mind and pray in detail.

Write down your prayer requests to better focus your mind and pray in detail.See omnystudio.com/listener for privacy information.

Write down your prayer requests to better focus your mind and pray in detail.

Scripture: Genesis 15:1-6; Matthew 13:1-9 Text: Heidelberg Catechism, Lord's Day 7 Theme: Without true faith, the narrow way is locked.

  AZ Bio Week & Life Sciences Innovation w/ Joan Koerber-Walker - AZ TRT S06 EP19 (281) 10-12-2025   Things We Learned This Week AZ Bio mission to improve life and bioscience, & make AZ a Top Ten Bioscience state AZ Bio Week 2025 - Oct. - 5 Days Talks, Events & Awards AZ Advances - nonprofit donation to biotech startups Aqualung Therapeutics is treating inflammation in the lungs, get people off ventilators & save lives Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Anuncia Medical has a Re-Flow product to help drain fluid from the brain, treats Hydrocephalus     Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   LKIN: https://www.linkedin.com/in/joankoerberwalker  www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations. In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and  represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015),  in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more.         AZBio:  Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org  MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.   AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.   Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.   Notes:   Seg 1   Biotech and life sciences industry in Arizona, has 3000 businesses and 36,000 employees. The economic impact in 2021 was $38.5 billion. AZ Bio would like to double, so by 2033, the impact would be $78 billion.   Examples of biotech companies in Arizona are Medtronic that makes medical devices, WL Gore, material sciences. Other companies in diagnostics, there are Sonoran Quest which does testing. This also Castle Bio Sciences, deals in cancer treatment. Some medicine companies are Bristol, Myers, and Calvari who deals in cancer drugs. Calvari is the bio science company of the year in 2024.   AZ Bio Science Week started in 2017. AZ Bio week starts Oct. 13 (2025) and has events daily from Monday to Friday.     Example of one of the many companies involved with AZ Bio week:   CND Life Sciences - CND's Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.   NIH - National Institute of Health gives grants or funding to universities, hospitals and even companies for medical research.   Takes time to build a medical device type product, a few years to decades.   Government is an important partner, that provides financial support. Examples are Medicare research, workforce help, and tax breaks. Many organizations like this are publicly funded with government and university help.  $25 billion in funding over the last 20 years in Arizona in bio investment. Government funded $5 billion, that's from state and federal sales tax at a penny per. $112 million funding to universities in 2022. Combination of industry, government and philanthropy. Discovery phase - university helps develop the IP and research. Technology is spun out of the university to corporate development by companies. The AZ Board of Regents owns the patents. They license the patents to companies. Then you have regulatory.  Distribution of a product. Successful products are profitable. They have a royalty that pays to the company, the university and the government. Example of this was the University of Florida created Gatorade in the 1970s and still gets royalties today. Process takes 10 to 15 years, with hundreds of people involved. Clinical trials of any type of drug takes years.   Creation of the Covid vaccine was an outlier, as many people had Covid at the time so it was very easy to put together big study groups       Seg 2   Examples of newer companies in biotech field –   Neo clinical stage company dealing in heart health with aortic artery for the abdomen.   Another new company is prim dealing in MCT deficiency, compound growth and they are in clinical and testing stages.   Drugs get tested through computer models, and then on animals. Always have to worry about safety and ethics. FDA has very strict rules. You do not put people at risk, after monitor, during test and post monitoring. There's high-level quality control.       AZ Bio has members that are in the bioscience industry with current companies   AZ Advances is about bio startups in early stage companies It's a 501 C nonprofit charity that is funding, internships, and education   Patient is not only the client, but the purpose for why biotech companies exist     Neuralink Corp. is an American neurotechnology company that has developed as of 2024 implantable brain–computer interfaces. It was founded by Elon Musk and a team of eight scientists and engineers. Neuralink was launched in 2016 and first publicly reported in March 2017.   Neuralink's first human patient, Noland Arbaugh, is an Arizona native who received his implant in January 2024 at the Barrow Neurological Institute in Phoenix. He will appear at Arizona Bioscience Week 2025     https://www.azbio.org/azbw2025     Events Summary:   Monday - Women in Biotech Leading Women: Biotech & Beyond Join us for an evening of conversation and connections with our community's leading women as we kick off Arizona Bioscience Week in style!   Tuesday - Fundraising Fundraising Strategies for Life Science Startups  A compelling narrative is crucial when you are fundraising and communicating with life science investors.  This Life Science Nation (LSN) Global Fundraising Bootcamp covers topics related to executing a successful fundraise for your startup.      Wednesday – AZ Bio awards, philanthropy, entertainment, and AZ Advances The 21st Annual AZBio Awards & AZAdvances After Party Celebrate with the Educators, Researchers, and Organizations that are making life better for people in Arizona and around the world.  Join us at the Phoenix Convention Center as we honor the 2024 AZBio Award Winners. Hundreds of health innovators and business leaders will be celebrating at the 20th Annual AZBio Awards.   Thursday -  AZAdvances   AZ Advances Health Innovation Summit This exclusive event will bring together health innovation leaders to share how are moving Arizona forward as we make life better for the people we serve.   AZ Advances: Arizonans are advancing life changing and life saving innovations along the path from discovery to development to delivery. AZAdvances is developing the funding that will help advance health innovations in Arizona today and for generations to come.  Charitable donations to the AZAdvances fund at the Opportunity Through Entrepreneurship Foundation, an Arizona based 501c3 public charity, are a way to support the creation of tomorrow's medical innovations.    Friday - Voice of the Patient Patients are the reason we do what we do.  Join the conversation on life science innovation from the patient perspective.        Seg. 3 Best of AZ Bio clips:   AZ Bio & Life Sciences Innovation w/ Joan Koerber-Walker - BRT S04 EP10 (172) 3-5-2023   Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   Full Show: HERE     Guest: Stan Miele President & CBO Aqualung Therapeutics Corp LKIN: HERE www.aqualungtherapeutics.com   Stan Miele Bio: A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries. Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc.  He was also President of Sucampo Pharma Americas for 6 years.   He was instrumental on some key licensing agreements for Sucampo, inclusive of the agreement with Abbott Japan, and also Takeda Pharmaceuticals (now Shire).  He is actively part of the team ensuring proper execution of clinical development, manufacturing, licensing, capital funding, alliances, and ensuring Aqualung meets all critical milestones.  He will be helping the company move toward accelerating the pipeline/platform technology and moving eNamptor™ toward commercialization.   Aqualung Therapeutics  Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung's strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.   Full Show: HERE       Seg. 4 – Clips from:  Preventing Cancer with a Vaccine w/ Stephen Johnston of Calviri  - BRT S04 EP17 (179) 4-23-2023   Guest: Stephen Johnston Founding CEO, Calviri Inc.  LKIN: HERE https://calviri.com/   Bio: Chief Executive Officer & Chairman of the Board Stephen Albert Johnston is the inventor of the Calviri's central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute's Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.     Calviri Inc.  We are determined to offer humanity a better life, free from cancer. While our goal is hugely ambitious, we are intensely driven to rid the planet of worry from cancer. Calviri's mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine.   Full Show: HERE       ReFlow to Help Treat Hydrocephalus w/ Elsa Abruzzo & Mark Geiger of Anuncia Medical - BRT S04 EP23 (186) 6-11-2023     Guest: Elsa Chi Abruzzo RAC, FRAPS – President Elsa Chi Abruzzo is a medical device executive, entrepreneur, and a founding member of Anuncia, Inc., Alcyone Therapeutics, Arthromeda, Inc. and Cygnus Regulatory. Elsa has a 30+ year successful product development, operations, regulatory, quality, and clinical track record in med tech Industries. Her experience includes leadership positions at Baxter, Cordis JNJ, CryoLife, Percutaneous Valve Technologies, AtriCure, InnerPulse, Merlin MD, Sapheon, and PTS Diagnostics. Elsa earned a BS in engineering from the University of Miami in Coral Gables, FL and is regulatory affairs certified and a Regulatory Affairs Professional Society Fellow, recognized for her leadership in Regulatory and Quality by MDDI.   https://anunciamedical.com/the-anuncia-story/#team https://www.linkedin.com/in/elsachiabruzzo/   https://anunciamedical.com/ About Anuncia Conceptualized in 2014 in collaboration with Boston Children's Hospital and spun out of Alcyone Therapeutics in 2018, Anuncia's patented portfolio of technologies are intended to provide peace-of-mind through innovation. Our core ReFlow™ technology uses a simple finger depression of a soft silicone dome located under the patient's scalp to produce a noninvasive, one-way flush of the patient's own CSF directed toward the ReFlow™ catheter to restore or increase CSF flow through a non-flowing shunt and potentially avoid emergency surgery.  Learn More     The name Anuncia comes from Panthera Uncia, the species name of the snow leopard. These animals live in mountainous regions of Asia and have been called by the World Wildlife Foundation “Guardians of the Headwaters” as they roam the headwater areas of the western basins. The origin of the word hydrocephalus comes from the Greek hudrokephalon, from hudro ‘water'+ kephalē ‘head'. The snow leopard, or Guardian of the Headwaters, is a symbol of Anuncia's dedication to improve daily quality of life for the millions of underserved patients with hydrocephalus and other CSF disorders, as well as their families, who suffer from the clinical, economic, and emotional burden of repeat revision brain surgery due to VP shunt occlusions.      Full Show: HERE           Best of Biotech from AZ Bio & Life Sciences to Jellatech: HERE   Biotech Shows: HERE   AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023      ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.

Bryan Hodgens, senior vice president and head of LIMRA research, explains why standalone long-term care coverage remains scarce, and how hybrid products are emerging as key solutions to help families and younger consumers manage rising caregiving and retirement risks.

Become a supporter of this podcast: https://www.spreaker.com/podcast/real-raw-with-dr-b--3086976/support.

Flight is an incredibly complex process that involves a combination of unique traits in birds all working together.

A new MP3 sermon from Answers in Genesis Ministries is now available on SermonAudio with the following details: Title: A Combination of Traits Subtitle: Answers with Ken Ham Speaker: Ken Ham Broadcaster: Answers in Genesis Ministries Event: Radio Broadcast Date: 10/3/2025 Length: 1 min.

Follow Everyday Encounters with the Lord on Facebook.

Clinical trials can present many challenges for patients–particularly injections.Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII, discuss nuance, challenges and opportunities of autoinjectors and combination drug delivery systems.Additionally, they advocate that drug delivery systems enter the conversation earlier in clinical development stages given interdependencies. This episode is presented in partnership with PII.Host⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestsOliver Eden, Senior Business Unit Director, JabilTravis Webb, Chief Scientific Officer, PIIDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Visit our website:https://www.thewealthwarehousepodcast.com/Fresh off the annual South Dakota pheasant trip, Dave and Paul unpack how time in the field mirrors smart money habits. From planning that survives “first contact,” to keeping dry powder ready so you can seize opportunities, to teaching kids stewardship and building legacy, this episode ties hunting camp lessons directly to the Infinite Banking Concept (IBC). Expect talk on independence, autonomy, privacy, patience & timing, and why liquidity you control beats balances that just “look good on paper.”Becoming Your Own Banker by Nelson Nash:https://infinitebanking.org/product/becoming-your-own-banker/ref/46/Episode Highlights:0:00 - Teaser & open2:17 - The crew: annual trip, fellowship, and why like-minded matters3:38 - How the hunt parallels IBC4:52 - Healthy disagreements (Bitcoin, moon landing) + shared values6:22 - The common thread7:00 - Independence, autonomy, privacy & healthy skepticism8:39 - Legacy and making memories with your kids9:31 - Planning meets reality12:00 - Translating hiccups to IBC13:16 - Patience & timing14:23 - Loaded shotgun vs. locked-up 401(k) liquidity15:53 - Fancy gear vs. dry powder16:34 - Getting better each year = older policies perform better17:24 - Stewardship and teaching the next generation18:02 - Accessing capital without interrupting growth22:02 - Save 30% rule: habits that build wealth22:32 - Seeking independence from commercial banking23:50 - Why IBC contributors may fuel less inflation24:57 - Hunters' autonomy as a money mindset28:27 - Episode wrap-upABOUT YOUR HOSTS:David Befort and Paul Fugere are the hosts of the Wealth Warehouse Podcast. David is the Founder/CEO of Max Performance Financial. He founded the company with the mission of educating people on the truths about money.David's mission is to show you how you can control your own money, earn guarantees, grow it tax-free, and maintain penalty-free access to it to leverage for opportunities that will provide passive income for the rest of your life.Paul, on the other hand, is an Active Duty U.S. Army officer who graduated from Norwich University in 2002 with a B.A. in History and again in 2012 with a M.A. in Diplomacy and International Terrorism. Paul met his wife Tammy at Norwich.As a family, they enjoy boating, traveling, sports, hunting, automobiles, and are self-proclaimed food people.Visit our website:https://www.thewealthwarehousepodcast.com/Catch up with David and Paul, visit the links below!Website: https://infinitebanking.org/agents/Fugere494 https://infinitebanking.org/agents/Befort399LinkedIn: https://www.linkedin.com/in/david-a-befort-jr-09663972/ https://www.linkedin.com/in/paul-fugere-762021b0/Email:davidandpaul@theibcguys.com

Osteosarcoma Webinar Series: Amy Armstrong, MD, a pediatric oncologist at Siteman Kids, joins us on OsteoBites to discuss an open-label, cohort-sequential dose-escalation and dose-confirmation Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma and osteosarcoma. She will review background, patient selection, treatment plan and study calendar for this clinical trial.Dr. Amy Armstrong is a pediatric oncologist who directs the Solid Tumor Program at Siteman Kids, affiliated with St. Louis Children's Hospital, as well as co-directs the Adolescent and Young Adult Sarcoma Program in collaboration with Siteman Kids and Siteman Cancer Center. She is an Associate Professor of Pediatrics at Washington University in St. Louis and has research interests in Neurofibromatosis Type 1-related plexiform neurofibromas, renal tumors, and sarcomas found most commonly in the adolescent and young adult population. Dr. Armstrong serves as site Principal Investigator for the Children's Oncology Group, Neurofibromatosis Clinical Trials Consortium and National Pediatric Cancer Foundation and is invested in conducting and developing clinical trials to serve a diverse range of solid tumors in both the upfront and relapsed setting.

Fred Bell, CEO of Elemental Altus Royalties (TSX.V:ELE) (OTCQX:ELEMF), and Dave Cole, CEO of EMX Royalty Corp (NYSE American: EMX) (TSXV: EMX), both join me to unpack the key transaction details, synergies, and growth profile emerging from the business combination of both companies into the emerging Elemental Royalty Corp.  In the new combined entity, Dave will be the CEO, and Fred will be the President and COO, with the balance of the management team and board being a solid blend of the 2 companies current teams.   Dave starts us off with the big-picture rationale for this merger, creating a larger royalty company of scale, graduating up to the mid-tier category, with more analyst coverage and liquidity, a better cost of capital, the financial strength from the backing of the key strategic shareholder Tether Investments, and the potential to rerate in the future to a better price to net asset value multiple more in alignment with larger royalty peers.   Fred then takes us through the transaction specifics of the merger, including the recent financing, share roll back, and US big board exchange listing that were all announced earlier this month, in concert with this business combination. Fred also outlines the importance of having Tether Investments as their key strategic shareholder, and they financially backstop the kinds of accretive acquisitions that they can now go after. He also explains why they made the choice to establish an institutional account to gain exposure to Tether Gold (XAUt), a tokenized asset backed 1:1 by physical gold, to diversify the Company's treasury and increase exposure to rising gold prices with enhanced liquidity and efficiency.   We also dive into updates on their key cornerstone royalty partner projects: Timok, Laverton, Karlawinda, and Caserones. the organic development growth still on tap in their portfolio of royalties, the future upside of the continued royalty generation strategy, and a look ahead to future larger acquisitions than were possible for both companies up until the creation of this new combined vehicle.   If you have any follow up questions for Dave or Fred regarding the merger of Elemental Altus Royalties with EMX Royalty, into the new Elemental Royalty Corp, then please email them to me at Shad@kereport.com.   In full disclosure, Shad is a shareholder of both Elemental Altus Royalties and EMX Royalty Corp at the time of this recording, and may choose to buy or sell shares at any time.   Click here to learn more about the Elemental Altus and EMX Royalty merger   Click here to view recent news on Elemental Altus Royalties   Click here to view recent news on EMX Royalty

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Association Between Fixed-Dose Combination Use and Medication Adherence, Health Care Utilization, and Costs Among Medicaid Beneficiaries.

Sun Peak Metals (TSX.V:PEAK - OTCQB:SUNPF) is making a major strategic move. President & CEO Greg Davis joins us to discuss the recently announced LOI with Saudi Discovery Company and the company's shift of focus to Saudi Arabia. Key points: Strategic pivot: Ethiopia's Shire project on hold under force majeure → shifting across the Red Sea. LOI details: Sun Peak shareholders ~60%, Saudi Discovery ~40% post-financing. Saudi portfolio: 6 granted licenses (~340 km²) + ~700 km² pending, all on VMS trends. Work plan: Mapping, geophysics, and drilling to start quickly with strong infrastructure in place. Supportive regime: Favorable permitting, tax/royalty terms, and government-backed financing incentives. Competitive edge: Early mover advantage in Saudi exploration, backed by a proven technical team with 20+ years in the Arabian Nubian Shield. For more market commentary & interview summaries, subscribe: The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/ Investment disclaimer This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

Happy September! This month for the September 2025 episode of the RCEM Learning Podcast Andy and Dave are talking about AI interpretation of ECG findings and managing acute asthma exacerbations. We are then going back to Becky and Chris rounding off the second part of their guideline on atrial fibrillation. We'll then end with New Online. If you'd like to email us, please feel free to do so here. After listening, complete a short quiz to have your time accredited for CPD at the RCEMLearning website! (02:13) New in EM - AI vs doctor in cath lab activations Accuracy of cath lab activation decisions for STEMI-equivalent and mimic ECGs: Physicians vs. AI (Queen of Hearts by PMcardio) (Shroyer et al., 2025) (18:00) Guidelines for EM - ESC Atrial Fibrillation (Part Two) ESC - 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) (ESC, 2024) (39:03) New in EM - Management of acute asthma exacerbations As-Needed Albuterol–Budesonide in Mild Asthma (LaForce et al., 2025) Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma (Cochrane Library, 2021) (54:00) New Online – new articles on RCEMLearning for your CPD Understanding Medical Cannabis: Mechanisms, Indications and Clinical Integration - David Tang Safe Sedation Procedures in Adults - Duncan Russell and Shobhan B Thakore Unusual Agitation in Final Year Student - Cathy Wield and Mark Horowitz

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This short episode covers the basics of electroconvulsive therapy.Hosts: Ravi Bhindi (CC3), Dr. Angad Singh (PGY2)Audio Editing: Dr. Angad Singh (PGY2)Show Notes: Dr. Angad Singh (PGY2)Time Stamps:(0:36) - What is ECT?(2:18) - Indications and efficacy(4:35) - Treatment course(4:32) - Combination treatment(6:33) - Medications to discontinue(8:16) - Contraindications(9:40) - Side effects(11:52) - Procedure(16:03) - SummaryResources:https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/electroconvulsive-therapyhttps://sunnybrook.ca/content/?page=psychiatry-electroconvulsive-therapy-ect-faqReferences:Andrade, C., Arumugham, S. S., & Thirthalli, J. (2016). Adverse Effects of Electroconvulsive Therapy. The Psychiatric clinics of North America, 39(3), 513–530.Brakemeier, E. L., Merkl, A., Wilbertz, G., Quante, A., Regen, F., Bührsch, N., van Hall, F., Kischkel, E., Danker-Hopfe, H., Anghelescu, I., Heuser, I., Kathmann, N., & Bajbouj, M. (2014). Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: a randomized controlled trial. Biological psychiatry, 76(3), 194–202.Espinoza, R. T., & Kellner, C. H. (2022). Electroconvulsive therapy. New England Journal of Medicine, 386(7), 667-672.Gill, S., Hussain, S., Purushothaman, S., Sarma, S., Weiss, A., Chamoli, S., ... & Loo, C. K. (2023). Prescribing electroconvulsive therapy for depression: Not as simple as it used to be. Australian & New Zealand Journal of Psychiatry, 57(9), 1202-1207.Janjua, A. U., Dhingra, A. L., Greenberg, R., & McDonald, W. M. (2020). The efficacy and safety of concomitant psychotropic medication and electroconvulsive therapy (ECT). CNS Drugs, 34(5), 509-520.Jelovac, A., Kolshus, E., & McLoughlin, D. M. (2013). Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 38(12), 2467–2474.Kolshus, E., Jelovac, A., & McLoughlin, D. M. (2017). Bitemporal v. high-dose right unilateral electroconvulsive therapy for depression: a systematic review and meta-analysis of randomized controlled trials. Psychological Medicine, 47(3), 518-530.Lam, R. W., Kennedy, S. H., Adams, C., Bahji, A., Beaulieu, S., Bhat, V., ... & Milev, R. V. (2024). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023: Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. The Canadian Journal of Psychiatry, 69(9), 641-687.Luchini, F., Medda, P., Mariani, M. G., Mauri, M., Toni, C., & Perugi, G. (2015). Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response. World journal of psychiatry, 5(2), 182–192.Tess, A. V., & Smetana, G. W. (2009). Medical evaluation of patients undergoing electroconvulsive therapy. New England Journal of Medicine, 360(14), 1437-1444.Zolezzi M. (2016). Medication management during electroconvulsant therapy. Neuropsychiatric disease and treatment, 12, 931–939.For more PsychEd, follow us on Instagram (@psyched.podcast),  Facebook (PsychEd Podcast), X (@psychedpodcast), and Bluesky (@psychedpodcast.bsky.social‬). You can email us at psychedpodcast@gmail.com and visit our website at psychedpodcast.org.

“SPINIPULATORS” combine spinning plus manipulating to wreak internal, and external havoc. These truth-distorters vomit false narratives designed to elevate themselves at the expense of other teammates. We can knock them off their perch with facts. Document timelines, conversations, and emails. If you persistently follow these three suggestions, you will eventually defeat most of these crafty narcissists.Support the show

Featuring an interview with Dr Jacob Sands, including the following topics: Management of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan (Dato-DXd) (0:00) Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract  Sands J et al. Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO 2024;Abstract 8623. Intracranial Efficacy of Dato-DXd for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations in the TROPION-Lung05 Study (7:23) Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.  Clinical Evidence Supporting the Combination of Dato-DXd with Immune Checkpoint Inhibition for Advanced NSCLC (12:12) Bessede A et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin Cancer Res 2024;30(4):779-85. Abstract Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501. Waqar SN et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). ASCO 2025;Abstract 8521. Current and Future Development of Antibody-Drug Conjugates in the Treatment of Lung Cancer (17:11) Tawfiq RK et al. Targeting lung cancer with precision: The ADC therapeutic revolution. Curr Oncol Rep 2025;27(6):669-86. Abstract CME information and select publications

Paul leaves Timothy in Ephesus so he could help the elders and the church in Ephesus to fight against false teachers and help them get back on track with the will of God. In chapter 2, Paul begins giving Timothy some instructions that will help him fight the battles and keep his conscience clear. In today's podcast, we break down two of the four things that Paul instructs Timothy to do on behalf of all men and women, kings, and all of those who are in authority. He tells Timothy these four things are also pleasing to God. The church today would greatly benefit from these four things if they would be obedient!

Summary:Join Jason Rogers and Garth Nichols for a deep dive into Phebe Trotman's book, Never Quit on a Bad Day. They explore the crucial role of resilience and showing up in leadership, particularly during difficult times. The discussion highlights the value of building a personal board of directors for mentorship and guidance, and the power of vulnerability in connecting with others. This episode is about leading with purpose, overcoming challenges, and finding joy in the journey.Top Takeaways:Showing Up Is Everything: A leader's presence, especially during tough times, is a powerful signal of support and commitment.Grit Is a Combination of Habits: Perseverance, positivity, and a commitment to continuous learning are the key components of true grit.The Power of Mentorship: A personal board of directors—a diverse group of mentors—provides invaluable perspectives and guidance for navigating challenges.Vulnerability Creates Connection: Leaders who are willing to be vulnerable foster trust and empower others to embrace their own struggles.Character Is Built Daily: Leadership and strong character are not inherent traits, but rather habits that are cultivated through consistent, daily effort.Sound Bites:"Character is a habit." "Keep leading and reading." "This book is an incredible gift." Chapters:00:00 - Introduction to Leadership and Bad Days 05:01 - The Importance of Showing Up 08:22 - Personal Board of Directors 11:14 - Resilience and Overcoming Challenges 13:09 - Leading with Joy and Authenticity 13:37 - Beards Book Club Outro (and a look at next week's book!)

Genetics are foundational to much of cancer treatment, and now both the environment surrounding the tumor as well as analysis of cancer cells shed into the blood may also be used to inform treatment as well. That's according to studies … A combination of strategies help determine best cancer treatment strategies, Elizabeth Tracey reports Read More »

今回のエピソードは： ・ヨシが変な食べ合わせでアウトした・ミステリアスなストレンジニュース・英語の可算／不可算のポイント解説【スポンサー】■世界で最も優れた 英語発音矯正アプリ「ELSA」ELSA Premium ライフタイムリンク（GoGoリスナーだけ！）⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://elsaspeak.com/inf/gogo-lifetime/?cache=no⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠■1年間有効のお手頃プラン！⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://elsaspeak.com/inf/gogo-eibu-premium/?cache=no⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠800回記念ビーチBBQパーティー参加登録はこちら：⁠⁠⁠https://www.55freebird.com/event-details/800kaikinen-bichibbq-party⁠⁠⁠ベアードビール（美味しいクラフトビール）クーポンコードは：GOGO10 (10% OFF)⁠⁠⁠⁠⁠https://bairdbeer.com/⁠⁠⁠⁠⁠　【ウェブサイト】問い合わせ/ ヨシのオンラインレッスン⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://55english.jp/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠エイブのサイト（オンラインレッスン・イベント等）⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.55freebird.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Free Bird English: Teacher Talk (エイブの100％英語番組）Apple:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tinyurl.com/yr48m3av⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tinyurl.com/27kstc5b⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠おしゃれアレルギーApple:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tinyurl.com/28mzcpjw⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tinyurl.com/ypkqp395⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠各種SNSは「GoGoエイブ会話」で検索してみてください♪【YouTubeチャンネル】GoGoエイブ 会話 YouTube チャネル：⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UCZSnkwixv3YMHVAsFheMSHg⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#EnglishLearning #EnglishPodcast #LanguageLearning #StudyEnglish #EnglishSpeak #EnglishPractice #EFL #ESL #英語学習 #podcast #FBEteachertalk #バイリンガル #ネイティブ

In this powerful episode, Brandy reveals one of the most profound discoveries in mind-body healing: there's actually a formula for healing. You'll hear a live coaching session with a beautiful volunteer where hidden emotional patterns are uncovered and shifted in real time—leading to relief, new awareness, and genuine empowerment. One of the most eye-opening insights is seeing how different combinations of emotions affect the body in different ways—and how key it is to shift the mindset at a deeper, subconscious level for lasting results in both emotional healing and physical health. You'll discover: Why stress alone isn't the real cause—and what's actually happening  How guilt, perfectionism, and fear of rejection combine to affect the body What “reverse emotional processing” is and why it makes change possible A moving live demonstration of emotions shifting into freedom How to begin applying these self-healing techniques to your own journey This session is a powerful reminder of the mind-body connection and how, when we truly learn to work with our minds, we can unlock natural healing and transformation. If you've ever struggled with chronic health challenges, emotional blocks, or guilt that weighs you down, this episode will inspire you to see what's possible. Tune in and discover how much power you truly have when you learn to decode what your body is trying to tell you.   Disclaimer: This podcast is for educational purposes only and is not a substitute for psychiatric or medical care. If you struggle with negative thoughts, chronic pain, or chronic health issues, please continue seeing your doctor as recommended. Think of self-healing and mind-body healing as ways to partner with your doctor—keeping them informed and working as a team—so you can feel empowered in your health journey and fully embrace what's possible through the power of your mind, emotions, and energy. Genuine change and consistent follow-through are key. Please enjoy this self-healing podcast. IMPORTANT NOTE: We understand that some may believe mind-body healing is impossible. Therefore, if you would like to see images of individuals using their minds to relieve pain, you can check out this medical journal. It includes images from some of Brandy's case studies. If you want to learn how to use your mind to heal yourself, you can check out the training on Brandy's website. Each week, Brandy publishes a volunteer episode where she coaches a volunteer to heal themselves using their own mind. In addition, Brandy shares a quick IQ episode (Insights and Questions) where she answers listener questions or delves deeper into insights on working with the mind for healing. Additional links and resources: Click here to begin "Finding the GIFT in Self-Healing™" https://brandygillmore.com/healing Join the FREE Breakthrough 90-Minute "GIFT Mind-Body Healing™ Masterclass" Training: https://brandygillmore.com/gift-mind-body-healing-masterclass The GIFT Method™ Online Video Series: Heal Yourself. Change Your Life. https://brandygillmore.com/gift-method-healing Website: https://brandygillmore.com TEDx Talk: https://brandygillmore.com/tedx Social Media and Additional: Facebook: https://facebook.com/brandy.gillmore/ IG: https://www.instagram.com/brandygillmore/ X ~ (Twitter): https://twitter.com/BrandyGillmore Additional classes and services: Heal & Transform Your Self-Love and Relationships with GIFT Alternative Therapy and Mind-Reprogramming (GIFT ATMR)™:  https://brandygillmore.com/gift-atmr Gillmore Internal Freedom Technique (GIFT)® : https://brandygillmore.com/gillmore-internal-freedom-technique/ Additional Courses: https://brandygillmore.com/courses-workshops VIP Monthly Coaching https://brandygillmore.com/vip-coaching/ Please remember that genuine change and follow through are key for self-healing results. If you struggle with negative thoughts or have a chronic health issue or chronic pain, please do not avoid seeing your doctor. Instead, your goal with self-healing should be to continue to see your doctor as recommended and blow their mind with what you are capable of with your mind and with the power of mind-body healing. Please enjoy this self-healing podcast. Topics: relationship healing, how to improve relationships, emotional triggers in relationships, mind-body connection, creating love and connection, relationship advice for healing, practical relationship tips, energy in relationships, healing relationships with mindset, stop relationship patterns, mind-based relationship tools, relationship transformation tips, Brandy Gillmore, Brandy Gillmore relationship advice, self-healing and relationships, communication in relationships, improve relationship connection, relationship mindfulness, break negative relationship cycles

It is this combination of praise and word that will inflict vengeance and punishment on the enemies of our lives and our destinies

Andy and Randy talk about Jessie Bates and Leonard Floyd being paired with guys like Xavier Watts, Billy Bowman, James Pearce, and Jalon Walker, and how that balance can create strong defenses sometimes.

In this episode of Let's ComBinate: Drugs + Devices, we welcome back Susan Neadle, author of The Combination Products Handbook. Susan explores the persistent and evolving challenge of terminology in combination products—a problem that continues to create confusion and regulatory risk even in 2025.Susan emphasizes the need for alignment on terminology and regulatory expectations, highlighting that true progress requires a science- and risk-based perspective. The discussion also covers how GMP requirements are interpreted differently in pharma versus medtech, the ongoing challenges of global harmonization, and why cohesive language is essential for compliance, inspection readiness, and effective product development.Episode Chapters00:00 Introduction and Welcome00:25 The Lexicon Problem in Drug-Device Combination Products01:01 Historical Efforts and Challenges02:12 Regulatory Frameworks and Definitions04:47 Industry and Regulatory Alignment Issues06:55 Science and Risk-Based Perspectives10:08 Terminology and Definitions in Practice14:05 Global Regulatory Differences17:22 Challenges in Harmonizing Standards23:13 Key Terms and Their Impact32:23 Conclusion and Contact InformationSusan Neadle is a recognized international Combination Products, Medical Device, and Digital Health expert with over 35 years industry experience. She has just published “The Combination Products Handbook: A Practical Guide” through Taylor & Francis Group/Routledge/CRC Press. Her leadership, innovation, and best practices have been recognized with several awards, including the 2022 ISPE Joseph X. Philips Professional Achievement Award for extraordinary contributions to the industry; 2021 TOPRA Award Finalist for Regulatory Affairs Excellence; and the Johnson Medal, Johnson & Johnson's highest honor for excellence in Research & Development. Susan retired from a distinguished and impactful career at Johnson & Johnson and is now Principal Consultant at Combination Products Consulting Services LLC, providing international quality, regulatory affairs, and design excellence services, to the biopharma, biotech, and medical device industries. She continues to fulfill her passion in this space as Chair of the ISPE Combination Products CoP, and Lead Author in Combination Products Working Groups through ASTM International and AAMI standards committees. Susan teaches curricula in Combination Products through UMBC, AAMI, and DIA, as well as customized training upon request. She is also active in multiple industry working groups including CPC, AFDO/RAPS, DIA, TOPRA and PQRI, and enjoys speaking at a variety of industry forums. Susan can be reached at sneadle@combinationprod.com Subhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee.For questions, inquiries or suggestions please reach out at letscombinate.com or on the show's LinkedIn Page.

The U.S. is running out of options to service the national debt. Secretary Bessent announced that we will now use revenue from tariffs to pay down budget deficits, rather than reinvest them into the economy. Some are treating this as welcome news. At the same time, the GOP has formed a working group to draft up a “sequel” to the Big Beautiful Bill to deepen cuts to Medicaid and federal student aid. They’ll do anything other than raise taxes on those that can afford them. But tariffs and more cuts to vital programs will only hasten economic decline, so team Trump is running out of options to stop the bleeding. And that means only one thing: Printing more money. But that’s more complicated than it seems and will lead to disastrous results. It does explain, however, why Trump is so desperate to take over the Federal Reserve. Chapters Intro: 00:00:57 Post Show Musings: 00:32:55 Outro: 00:47:04 Resources UNFTR.com Sign the Petition To Stop the Senate From Passing These Bills Politico: House Republicans want another megabill. One GOP senator says it could be ‘damaging.’ X: Republican Study Committee Republican Study Committee: One Big Beautiful Sequel: RSC Chairman Launches Working Group for Second Reconciliation Bill Brookings: What is the repo market, and why does it matter? St. Louis Fed: What Is Yield Curve Control? Treasury: Treasury Announces Marketable Borrowing Estimates UNFTR Quickies UNFTR Discord -- If you like #UNFTR, please leave us a rating and review on Apple Podcasts and Spotify: unftr.com/rate and follow us on Facebook, Bluesky, TikTok and Instagram at @UNFTRpod. Visit us online at unftr.com. Join our Discord at unftr.com/discord. Become a member at unftr.com/memberships. Buy yourself some Unf*cking Coffee at shop.unftr.com. Visit our bookshop.org page at bookshop.org/shop/UNFTRpod to find the full UNFTR book list, and find book recommendations from our Unf*ckers at bookshop.org/lists/unf-cker-book-recommendations. Access the UNFTR Musicless feed by following the instructions at unftr.com/accessibility. Unf*cking the Republic is produced by 99 and engineered by Manny Faces Media (mannyfacesmedia.com). Original music is by Tom McGovern (tommcgovern.com). The show is hosted by Max and distributed by 99.Support the show: https://www.unftr.com/membershipsSee omnystudio.com/listener for privacy information.

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/

Today, I'm taking you on a solo exploration into the world of extra virgin olive oil—a topic that's both well-loved in ancestral diets and increasingly backed by cutting-edge science. Inspired by my recent interview with TJ Robinson of the Fresh Pressed Olive Oil Club, I started looking deeper into what makes extra virgin olive oil so powerful for health and longevity. What I found truly surprised me: there's a wealth of research showing just how crucial high-quality olive oil is to the benefits of the Mediterranean lifestyle. Try the Fresh Pressed Olive Oil Club and get a $39 bottle of extremely fresh olive oil for just $1 for shipping. No catch, no subscription required. Go to GetFreshLongevity.com   Resources from the episode: Bioactive Compounds and Quality of Extra Virgin Olive Oil Protective Effects and Benefits of Olive Oil and Its Extracts on Women's Health EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy? Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil FREE Peptide Book: natniddam.com/free   What we discuss: Mediterranean diet and lifestyle overview ... 00:04:30 What makes olive oil "extra virgin" ... 00:08:15 Key bioactive compounds in olive oil ... 00:12:03 Major health benefits and research highlights ... 00:19:10 GLP-1 activation, gut, and heart health ... 00:20:17 Olive oil's role in women's health and longevity ... 00:21:28 Ways to use extra virgin olive oil ... 00:24:16 Final tips and episode close ... 00:28:39   Our Amazing Sponsors: Berberine Breakthrough by BiOptimizers - Take 15 min. before a meal and your body will push carbs and glucose into your muscles to be used as fuel instead of turning them into fat. Enjoy more stable energy without the post-meal crash. Visit bioptimizers.com/bionat and enter the code BIONAT to get 10% off your order.   More from Nat:  YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

Got Questions?⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://calendly.com/conrad-rodriguez/30-minute-coaching-session⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Get THE BEST PENIS EXTENDER ON THE MARKET! ⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICK HERE⁠⁠⁠⁠⁠⁠⁠⁠⁠

In this episode of Let's Combinate, host Subhi Saadeh is joined by long-time friend and Senior Technical Program Manager Joey Frechin, who brings a wealth of experience in med tech consulting. They discuss the intricacies of risk assessments for medical devices and drugs, focusing on differences and improvements in methodologies over the years. Joey shares insights on the challenges of aligning risk processes across different organizations and the importance of adaptable strategies. He also recounts his unique career path that blends design engineering with extensive process and risk management expertise. The conversation covers trends such as the shift toward off-the-shelf platforms and the balancing act between innovative design and market readiness. Joey emphasizes the value of stepping into roles and tasks that others may overlook, which has been key to his professional growth.00:00 Welcome and Introduction00:49 Discussing Risk Assessments in Med Tech04:34 Challenges in Aligning Risk Processes09:44 Understanding P1 and P2 in Risk Management12:55 Joey's Career Journey and Strategic Choices24:12 Trends in Combination Product Design31:48 Conclusion and Where to Find JoeyJoey Frechin is a technical program lead in the medical device and combination product development space.https://www.linkedin.com/in/joey-frechinSubhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee.For questions, inquiries or suggestions please reach out at letscombinate.com or on the show's LinkedIn Page.

Cellulite is one of the most common concerns we see in the world of aesthetics — but there's a lot of misinformation about what causes it and how to address it. In this episode of Plastic Surgery Untold, we're breaking down the truth about cellulite, how it relates to modern BBL trends, and why it's not just a “being out of shape” issue. From understanding the complex web of fibrous bands beneath the skin to exploring the role of hormones, skin laxity, and volume changes, we're covering the anatomy of cellulite and the latest treatment options that actually work. Whether you're dealing with dimples on the butt, thighs, or both, this conversation is packed with insights to help you target the root cause and get results you love. Highlights from this episode: • What cellulite actually is and why it happens • The difference between cellulite, skin laxity, and volume changes • Why targeted treatment is key for lasting results • How non-surgical office procedures can transform the contour of the butt and legs • Combination approaches that address all three concerns for the best outcome Listen anywhere you get your favorite podcasts or watch on YouTube for visuals and case examples.

Brazilian butt lifts have been one of the most transformative procedures in aesthetics, and with new technology, they're safer than ever. In this episode of Plastic Surgery Untold, we're breaking down how the combination of advanced anatomical understanding and ultrasound guidance has completely changed the game for BBL safety and results. A BBL offers powerful total-body transformation — subtracting fat from areas like the abdomen or love handles, and adding it to the hips and buttock for enhanced curves. In recent years, the focus has shifted from simply increasing size to creating shape, balance, and athletic definition. Key factors in today's BBL approach: Ultrasound guidance for precise, real-time fat placement in safe compartments Shape over size for a fit, natural look that complements the whole body Combination treatments like skin tightening, cellulite reduction, and targeted fat transfer for complete contouring By staying above the muscle and placing fat only in fat compartments, modern BBLs avoid dangerous complications while achieving smooth, shapely results. Whether paired with tummy tucks, rib contouring, or skin tightening, this evolution in technique means patients can look as good as they feel. Listen to the full episode on Plastic Surgery Untold wherever you get your favorite podcasts — and see why the BBL remains one of the most in-demand procedures today.

Scared of missing out on the growth rally? Tracey Ryniec, Zacks Value Stock Strategist, screened for cheap stocks with growth. (0:30) - Stock Screener: Can You Find Strong Value Stocks With Growth? (6:45) - Tracey's Top Stock Picks (22:25) - Episode Roundup: ADDYY, ARRY, NX